PureTech Health

PRTC

BOSTON--(BUSINESS WIRE)--PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference.

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.

PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2025.

BOSTON--(BUSINESS WIRE)--PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors.

BOSTON--(BUSINESS WIRE)--PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia.

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.

BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300).